UARK 2005-05, coagulation-related effects of Velcade [bortezomib] treatment in patients with relapsed or refractory multiple myeloma.

Trial Profile

UARK 2005-05, coagulation-related effects of Velcade [bortezomib] treatment in patients with relapsed or refractory multiple myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2011

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacodynamics
  • Acronyms UARK
  • Most Recent Events

    • 11 Aug 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 15 May 2009 Actual patient number added (11) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top